Last month, a second phase 3 blow for Marinus Pharmaceuticals prompted the Pennsylvania-based drugmaker to turn an eye toward ...

UC's Brandon Foreman, MD, explained the trial focused on status epilepticus (SE), a disorder he described as "seizures that don't stop." Seizures are the second most common neurologic emergency in ...

Nat Clin Pract Neurol. 2007;3(9):505-516. Myoclonic Status Epilepticus. Myoclonic SE is characterized by continuous, usually generalized, myoclonias of cortical origin. The inclusion of myoclonic ...

One of the trial’s co-primary endpoints—cessation of status epilepticus (SE) within 30 minutes—was successfully met, with 80% ...

RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) is set to present significant findings from its Phase 3 RAISE trial ...

癫痫持续状态（Status epilepticus，SE）是以持续癫痫发作并可能造成神经系统甚至多脏器损伤为特征的儿童神经系统危重症之一 ...

We’re exploring some of the most common triggers of seizure clusters and practical tips on how to avoid or manage these risks ...

The co-primary endpoints were the proportion of patients with status epilepticus (SE) cessation within 30 minutes and the proportion of patients not progressing to IV anesthesia within 36 hours of ...

clearance for diagnosing electrographic status epilepticus. Subsequently, the Clarity algorithm received a New Technology Add-on Payment (NTAP) from the Centers for Medicare and Medicaid Services (CMS ...

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and ...

A fundraising campaign has been set up for a brave 11-year-old Waterford city boy who suffers from severe epilepsy and other ...

“In 2024, our Phase 3 data in status epilepticus and tuberous sclerosis complex showed meaningful clinical activity in certain refractory patients, however, the trials did not meet the thresholds for ...